Expressing support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This House resolution expresses support for making antiphospholipid syndrome (APS) testing a standard part of prenatal screening for all pregnant women. It calls on professional medical associations like the American College of Obstetricians and Gynecologists (ACOG) to update their clinical guidelines to include routine APS testing during pregnancy.
Who Benefits and How
Pregnant women benefit by potentially receiving earlier detection of APS, an autoimmune disorder that can cause serious pregnancy complications including miscarriage, stillbirth, and preeclampsia. Clinical diagnostic laboratories like Quest Diagnostics and LabCorp would benefit financially from increased demand for APS testing services. Maternal-fetal medicine specialists and obstetricians may see expanded scope of practice in prenatal screening.
Who Bears the Burden and How
Health insurance providers would face increased costs from covering additional prenatal testing for millions of pregnant women annually. Professional medical associations like ACOG and the Society for Maternal-Fetal Medicine would need to dedicate resources to reviewing evidence and updating their clinical practice guidelines. Healthcare systems and providers would need to integrate new testing protocols into their prenatal care workflows.
Key Provisions
- Expresses House support for routine APS testing during prenatal care
- Calls on medical professional associations to revise their guidelines to include APS screening
- Non-binding resolution with no legal requirements or appropriations
- Focused on improving detection of autoimmune disorders that complicate pregnancy
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Expresses support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening and calls on medical associations to update their recommendations
Who Benefits
- Pregnant women at risk for APS
- Maternal health advocates
- Diagnostic testing companies
Who Bears Costs
- Healthcare systems (potential cost of additional testing)
- Medical associations (need to review and update guidelines)
Key Policy Areas
Healthcare, Maternal Health, Preventive Medicine
Primary Purpose
Expresses support for testing for antiphospholipid syndrome (APS) as a standard part of prenatal screening and calls on medical associations to update their recommendations
Policy Domains
Legislative Strategy
"Non-binding resolution to encourage medical community to adopt APS testing in prenatal care"
Identified Gains
- Pregnant women at risk for APS
- Maternal health advocates
- Diagnostic testing companies
- Obstetric healthcare providers
Identified Costs
- Healthcare systems (potential cost of additional testing)
- Medical associations (need to review and update guidelines)
Sponsors
Legislative Progress
In CommitteeMrs. Cammack (for herself, Ms. Kamlager-Dove, Mrs. Kim, Ms. Pettersen, …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Clinical diagnostic laboratories offering prenatal testing
Professional medical associations (ACOG, SMFM, etc.)
Pregnant women at risk for APS and pregnancy complications
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology